First page of the Report "Expert Analysis: 22 years of FDA Drug GMP 483s"

Report – Expert Analysis: 22 years of FDA Drug GMP 483s

By

Jerry Chapman

,

This report looks into 22 years (2000 – 2022) of FDA Drug GMP 483s.

The analyses reviewed in this report can be used to target internal remediation and inspection preparation efforts; due diligence inspections; to target supplier and Contract Manufacturing Organization (CMO) inspections; training purposes; and myriad other compliance improvement efforts.

Logo of AMGEN
Logo of Abbvie
Logo of AstraZeneca
Logo of Baxter
Logo of Genentech
Logo of Lilly
Logo of Merck
Logo of Philips Healthcare
Logo of UCB
Logo of AMGEN
Logo of Abbvie
Logo of AstraZeneca
Logo of Baxter
Logo of Genentech
Logo of Lilly
Logo of Merck
Logo of Philips Healthcare
Logo of UCB
If you have trouble with the form, please contact events@redica.com.

Access the white paper

If you have trouble with the form, please contact events@redica.com.